Table 3.
Clinical features of patients with Myelofibrosis (2nd cohort)
| Clinical Features | Median [range] or No. (%) |
P | |
|---|---|---|---|
| No Splenectomy (n = 411) |
Splenectomy (N=50) |
||
| Age, years | 64 [20–86] | 59 [26–85] | 0.0011 |
| Age > 65 years | 179 (44) | 12 (24) | 0.008 |
| Male sex | 260 (63) | 29 (58) | 0.46 |
| Diagnosis | 0.34* | ||
| • PMF | 303 (74) | 32 (64) | |
| • Post-PV MF | 61 (15) | 10 (20) | |
| • Post-ET MF | 47 (11) | 8 (16) | |
| Performance Status > 1 | 46 (11) | 4 (8) | 0.30 |
| Constitutional Symptoms | 180 (44) | 25 (50) | 0.40 |
| Hb, g/dL | 10.0 [6.2–18] | 10.0 [7–16] | 0.89 |
| Hb< 10g/dL | 157 (38) | 17 (34) | 0.56 |
| WBC, × 109/L | 9.4 [0.4–191] | 11.8 [1.3–70.6] | 0.02 |
| WBC > 25 × 109/L | 59 (14) | 14 (28) | 0.01 |
| Platelets, × 109/L | 214 [3–1299] | 239 [16–1958] | 0.24 |
| Platelet < 50 × 109/L | 54 (13) | 7 (14) | 0.83 |
| PB Blasts, % | 0 [0–16] | 0 [0–6] | 0.70 |
| PB Blasts > 1% | 199 (48) | 23 (46) | 0.74 |
| BM Blasts, % | 2 [0–17] | 1 [0–8] | 0.99 |
| BM Blasts ≥10% | 22 (5) | 0 (0) | 0.15 |
| LDH, IU/L | 1215 [189–10353] | 1445 [378–5059] | 0.22 |
| Transfusion Dependency | 100 (24) | 12 (24) | 0.95 |
| Exposure to Alkylating Agents | 4 (1) | 4 (8) | 0.006 |
| Cytogenetic Risk Group | 0.36* | ||
| • Low Risk | 290 (70) | 31 (62) | |
| • Intermediate Risk | 59 (14) | 9 (18) | |
| • Poor Risk | 21 (5) | 5 (10) | |
| • No metaphases or not done | 41 (10) | 5 (10) | |
| DIPSS Risk Group | 0.99* | ||
| • Low | 59 (14) | 7 (14) | |
| • Intermediate-1 | 180 (44) | 22 (44) | |
| • Intermediate-2 | 134 (33) | 17 (34) | |
| • High | 38 (9) | 4 (8) | |
*
p-value for trend